Peptides for Veterinary Applications

From post-surgical healing in dogs to tendon repair in performance horses, peptides are gaining ground in veterinary medicine. Here is what the research supports, what remains experimental, and what pet owners and equine professionals should understand.

Why Peptides Are Gaining Attention in Veterinary Medicine
FDA-Approved and Established Peptide Uses in Animals
BPC-157 for Dogs: The Most-Discussed Veterinary Peptide
TB-500 (Thymosin Beta-4) in Equine Medicine
- Mechanism and Equine Research
- Doping Concerns in Horse Racing
GHK-Cu: Wound Healing Across Species
GLP-1 Agonists and Pet Obesity
Antimicrobial Peptides: Fighting Resistance in Livestock
- Why AMPs Matter for Animal Agriculture
- Applications by Species
Cancer Immunotherapy: Peptide Vaccines for Dogs
Comparison: Veterinary Peptides at a Glance
Safety Considerations for Pet Owners
FAQ
The Bottom Line
References

Why Peptides Are Gaining Attention in Veterinary Medicine

Veterinary peptide research runs about 5–10 years behind human medicine, but it is accelerating fast [1]. The reasons mirror what has driven interest on the human side: aging pet populations with chronic conditions, the antimicrobial resistance crisis in livestock, and growing demand for targeted therapies with fewer side effects than conventional drugs.

A considerable number of peptides used in human medicine are also applied in veterinary contexts [2]. Some, like ACTH and TRH, have been diagnostic staples for decades. Others — BPC-157, TB-500, GLP-1 agonists — represent a newer wave of interest driven partly by pet owners who have heard about these peptides through human wellness communities.

The difference between hype and help comes down to evidence. This guide sorts the established from the experimental.

FDA-Approved and Established Peptide Uses in Animals

Diagnostic Peptides

Several peptide-based diagnostics have been part of veterinary practice for years [2]:

Peptide	Species	Use
Protirelin (TRH)	Dogs, horses	Thyroid disorder diagnosis; equine Cushing's disease (PPID) screening
Cosyntropin (synthetic ACTH)	Dogs, cats, horses	Adrenal function testing, Cushing's/Addison's disease diagnosis
C-peptide (canine)	Dogs	Monitoring endogenous insulin production in diabetic dogs
Pentetreotide (111-In labeled)	Dogs	SPECT imaging to locate canine insulinomas

These are well-validated uses with decades of clinical experience behind them. They form the backbone of endocrine diagnostics in small animal and equine practice.

Peptide Antibiotics

Peptide-based antibiotics have a long history in veterinary medicine [3]:

Polymyxins (polymyxin B, colistin): Used against gram-negative infections, particularly in livestock. Colistin has been called a "last resort" antibiotic in both human and veterinary medicine.
Bacitracin: Topical use in companion animals; historically used as a growth promoter in livestock (now restricted in many countries).
Glycopeptides (vancomycin): Reserved for serious resistant infections.

Peptide Vaccines

Peptide-based vaccines are one of the most promising frontiers in veterinary medicine. They offer advantages over traditional whole-pathogen vaccines: easier manufacturing, better shelf stability, defined chemical composition, and lower risk of adverse reactions [4].

In livestock, synthetic peptide vaccines are being developed for foot-and-mouth disease, avian influenza, and other economically significant pathogens. In companion animals, cancer vaccines using peptide targets are now in advanced clinical trials (covered in detail below).

BPC-157 for Dogs: The Most-Discussed Veterinary Peptide

What the Research Shows

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide originally isolated from human gastric juice. It is also found in the canine digestive system [1]. Most of the existing data comes from rodent studies, but the results have captured the attention of both integrative veterinarians and pet owners.

In animal models, BPC-157 has demonstrated [5]:

Faster healing of ligaments, tendons, and soft tissue
Reduced inflammatory cytokines in joint degeneration models
Improved vascularization through upregulation of VEGF (vascular endothelial growth factor)
Neuroprotective effects in certain injury models
Stability in gastric acid, allowing both oral and injectable administration

Unlike many peptides that require complex delivery systems, BPC-157 remains active in the stomach — a practical advantage for dosing animals that resist injections.

Conditions Being Explored

Integrative veterinarians are exploring BPC-157 for several conditions in dogs [1, 6]:

Post-surgical recovery: Accelerating healing after orthopedic procedures
Arthritis and joint degeneration: Reducing inflammation and supporting tissue repair
Chronic gut issues: Leaky gut, inflammatory bowel disease, and chronic diarrhea
Soft tissue injuries: Ligament tears, tendon strains, and muscle damage
Skin conditions: Slow-healing wounds and inflammatory skin flares

Limitations and Unknowns

Despite the excitement, significant gaps remain [5]:

No controlled clinical trials in dogs. Virtually all published data comes from rats and mice. Extrapolating rodent results to canine physiology is common in veterinary research, but it is not a substitute for species-specific studies.
No standardized veterinary dosing protocols. Doses currently used are borrowed from rodent studies and scaled by body weight — an imprecise method.
No FDA or USDA approval for veterinary use. BPC-157 is classified as an experimental compound.
Tumor growth concern. Because BPC-157 promotes blood vessel formation and tissue growth, it could theoretically accelerate the progression of existing tumors. A veterinary check-up before starting therapy is important [1].
Quality control. The same contamination and mislabeling problems that affect human peptide products apply to veterinary-marketed versions.

TB-500 (Thymosin Beta-4) in Equine Medicine

Mechanism and Equine Research

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration, blood vessel formation, and wound repair. The active segment — a 7-amino-acid sequence called LKKTETQ — drives its biological effects [7].

In equine medicine, TB-500 has attracted particular interest for performance horses because of its proposed effects on [7]:

Tendon and ligament repair: Promoting cell migration to injured connective tissue
Inflammation reduction: Modulating the inflammatory response in overworked joints
Soft tissue recovery: Accelerating healing timelines after training injuries
Angiogenesis: Supporting new blood vessel formation in damaged tissue

Research in equine applications dates back to the 2000s. Studies on horses with thymosin-based compounds began even earlier, in the 1960s [7]. In practice, some equine veterinarians use TB-500 for horses recovering from tendon injuries, joint strain, and connective tissue fatigue.

However, no standardized dosing protocol exists for horses. Most protocols rely on limited published data, anecdotal reports, or individual veterinary judgment [7]. Traditional therapies — rest, controlled exercise, physiotherapy, PRP, and stem cell treatments — have stronger evidence bases and are often used alongside TB-500 rather than being replaced by it.

Doping Concerns in Horse Racing

TB-500's tissue-repair properties make it an attractive — and prohibited — substance in equine sports. Racing authorities worldwide have banned it, and research has focused heavily on developing detection methods [8].

A validated liquid chromatography-mass spectrometry method can identify TB-500 and its metabolites in equine urine and plasma, detecting the artificial acetylation that distinguishes synthetic TB-500 from naturally occurring thymosin beta-4 [8]. Athletes (human or equine) caught using TB-500 face serious consequences.

GHK-Cu: Wound Healing Across Species

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first identified in human plasma in 1973. It has been tested across multiple animal species with consistent wound-healing results [9]:

Dogs: Accelerated healing of skin wounds, hair follicles, gastrointestinal tissue, bone, and foot pads
Rats and mice: Systemic wound-healing effects — GHK-Cu injected in one body area improved healing at distant sites
Pigs: Enhanced skin wound closure
Rabbits: Improved wound contraction and granular tissue formation

One notable finding: GHK-Cu produces systemic healing effects in animal models. An injection in a rat's thigh muscle improved wound healing in its ears [9]. This systemic action suggests mechanisms beyond simple local tissue repair.

In veterinary practice, GHK-Cu is most commonly used topically for wound management. Its safety profile is favorable — the estimated lethal dose is roughly 300 times higher than the effective therapeutic dose [9]. A 2003 study by Canapp et al. in Veterinary Surgery specifically examined topical GHK-Cu effects on ischemic wounds, finding faster healing and reduced inflammatory markers.

The main limitation for clinical use is enzymatic breakdown. Wound environments often contain carboxypeptidase enzymes that degrade GHK-Cu rapidly, reducing its effectiveness in chronic or infected wounds [9].

GLP-1 Agonists and Pet Obesity

The Scope of the Problem

Pet obesity has reached epidemic levels. According to the Association for Pet Obesity Prevention, 59% of U.S. dogs and 61% of cats are overweight or obese [10]. Obesity in companion animals leads to diabetes, heart disease, joint problems, and shorter lifespans — the same constellation of problems seen in humans.

Where the Research Stands

The success of GLP-1 drugs like semaglutide in human obesity has naturally raised the question: could these work for pets?

The answer is "probably, but not yet." Here is where the research stands [10, 11]:

Liraglutide in dogs: A 2025 clinical study tested liraglutide (another GLP-1 agonist) in 21 neutered senior Golden Retrievers, evaluating effects on weight, metabolism, and antioxidant capacity
GLP-1 implants for cats: Okava Pharmaceuticals is running the MEOW-1 trial — testing a subcutaneous implant (OKV-119) that releases GLP-1 medication over six months in 50 cats. Results are expected in 2026, with a dog version in development
Diabetic animal studies: In diabetic dogs, GLP-1-based drugs reduced blood glucose and increased glucose uptake. In diabetic cats, they reduced glycemic variability and lowered the need for exogenous insulin [11]

No GLP-1 medications are currently approved for veterinary use. Semaglutide specifically has not been studied enough in dogs or cats to establish safety parameters [10].

Cost and Practicality

Even if GLP-1 drugs prove effective in pets, cost is a major barrier. Human GLP-1 medications run $900–$1,350 per month before insurance [10]. Few pet owners can sustain that expense, and pet insurance rarely covers experimental treatments.

Oral formulations and long-acting implants could change the equation. The Okava implant model — a single six-month device — would eliminate the need for daily or weekly injections, a significant advantage for both pet and owner. But these are still years away from commercial availability.

Antimicrobial Peptides: Fighting Resistance in Livestock

Why AMPs Matter for Animal Agriculture

Antimicrobial resistance (AMR) is one of the defining health threats of this century, and livestock agriculture is a major contributor. Global antimicrobial use in livestock could hit 143,481 tons by 2040 — a 29.5% increase from 2019 levels [12]. Resistant bacteria from farm animals can spread to humans through direct contact, food consumption, and contaminated water.

Antimicrobial peptides (AMPs) — sometimes called nature's antibiotics — offer a potential alternative. These short-chain amino acid sequences (typically 10–50 amino acids) punch holes in bacterial membranes through mechanisms that bacteria struggle to develop resistance against [12, 13].

Unlike conventional antibiotics, AMPs:

Are biodegradable (they break down into amino acids)
Have broad-spectrum activity against bacteria, fungi, and viruses
Kill bacteria rapidly
Also stimulate the host immune system
Show lower rates of resistance development

Applications by Species

Cattle

Mastitis treatment: Bovine myeloid antimicrobial peptides (BMAP-27, BMAP-28, BMAP-34) show activity against common mastitis pathogens including S. aureus, E. coli, and Streptococcus species [12]
Lactoferricin: A peptide from bovine lactoferrin that treats subclinical mastitis and shows activity against fungal pathogens
Tracheal antimicrobial peptide (TAP): A beta-defensin produced by respiratory epithelial cells that protects against bovine respiratory disease — though stress-induced cortisol can reduce its effectiveness

Swine

AMPs isolated from Bacillus subtilis show activity against Haemophilus parasuis, the cause of Glasser's disease [12]
Dietary supplementation with lactoferricin peptide (100 mg/kg feed) reduced gastrointestinal E. coli infections in pigs

Poultry

Microcin J25 (MccJ25): A bacterial RNA polymerase inhibitor that improved broiler growth and reduced intestinal damage from infection. At doses of 0.5–1.0 mg/kg, it reduced body weight loss by up to 70%, compared to 54.6% with antibiotic treatment [14]
AMPs are being explored as replacements for banned antibiotic growth promoters
Administration routes include oral, intraperitoneal, in ovo injection, and use as food bio-preservatives

Horses

Equine cathelicidins and defensins represent promising candidates for therapeutic development
Specific bioactive collagen peptides (PETAGILE) have been studied for equine osteoarthritis — a 12-week trial in 38 horses tested oral doses of 25 g and 50 g daily [15]

Cancer Immunotherapy: Peptide Vaccines for Dogs

One of the most exciting areas of veterinary peptide research is cancer immunotherapy. Cancer is a leading cause of death in dogs, and many canine cancers share biological features with human cancers — making dogs a valuable translational model.

EGFR/HER2 Peptide Vaccine (Yale/TheraJan)

The most advanced canine peptide vaccine targets EGFR and HER2 — proteins overexpressed in many canine cancers. Developed by Yale researcher Mark Mamula, this vaccine [16]:

Has been administered to over 600 dogs with minimal reported side effects
Is in clinical trials at 11 U.S. sites and one in Canada for osteosarcoma, hemangiosarcoma, and transitional cell carcinoma
Produced roughly 12-month median survival for osteosarcoma patients receiving palliative radiation plus vaccine (without amputation)
Generated a polyclonal immune response — multiple antibody types — making it harder for cancer to develop resistance
Is under USDA review, with full trial data expected in 2025

Checkpoint Inhibitors

The USDA recently granted a conditional license for gilvetmab (Merck Animal Health), a caninized monoclonal antibody against PD-1 — the first veterinary checkpoint inhibitor [17]. This opens the door for combination therapies pairing checkpoint inhibitors with peptide vaccines.

Telomerase Vaccine (pDUV5)

A DNA vaccine targeting telomerase reverse transcriptase (TERT) — overexpressed in 90%+ of canine cancer cells — generated strong, long-lasting immune responses when administered intradermally to healthy dogs [18].

These developments represent a genuine shift in veterinary oncology. Peptide-based cancer vaccines are inexpensive to produce, stable, and well-tolerated — three qualities that matter enormously in veterinary medicine where treatment costs directly affect access.

Comparison: Veterinary Peptides at a Glance

Peptide	Primary Species	Main Application	Evidence Level	Regulatory Status
ACTH/Cosyntropin	Dogs, cats, horses	Adrenal diagnostics	Established	Approved for diagnostic use
Polymyxins	Livestock, companion animals	Bacterial infections	Established	Approved
BPC-157	Dogs (primarily)	Tissue repair, gut healing	Preclinical (rodent data)	Not approved; experimental
TB-500	Horses (primarily)	Tendon/soft tissue repair	Preclinical + anecdotal	Not approved; banned in racing
GHK-Cu	Dogs, rats, pigs	Wound healing	Preclinical (multi-species)	Not approved for veterinary use
GLP-1 agonists	Dogs, cats	Obesity, diabetes	Early clinical trials	Not approved for animals
EGFR/HER2 vaccine	Dogs	Cancer immunotherapy	Phase II/III trials	USDA review pending
Collagen peptides	Horses, dogs	Osteoarthritis	Clinical studies	Available as supplements
AMPs	Livestock, poultry	Antimicrobial	Strong preclinical	Limited approvals

Safety Considerations for Pet Owners

If you are considering peptide therapy for your pet, keep these points in mind:

1. Work with your veterinarian. Peptides should not be administered without veterinary oversight. Even compounds with favorable safety profiles in animal studies can interact with existing conditions or medications.

2. Get a health screening first. Because peptides like BPC-157 promote tissue growth and blood vessel formation, they could theoretically accelerate existing tumors. A thorough veterinary exam — including bloodwork — should precede any peptide therapy [1].

3. Source matters. The same quality-control problems that plague human peptide products apply to veterinary versions. Look for products with certificates of analysis from independent labs. Avoid "research only" products marketed with a wink toward pet use.

4. Dose carefully. There are no standardized veterinary dosing guidelines for most experimental peptides. Doses calculated by simple body-weight scaling from rodent studies may not account for species-specific differences in metabolism, absorption, and elimination.

5. Know the legal reality. Experimental peptides are not FDA or USDA approved for animals. If your pet competes in any sport (agility, racing, field trials), many peptides are banned by governing bodies.

6. Consider proven alternatives first. For many conditions where peptides are being explored, established treatments exist. NSAIDs, physical rehabilitation, PRP therapy, and stem cell treatments all have more clinical data in veterinary populations than most peptides.

FAQ

Can I give my dog BPC-157? Some integrative veterinarians use BPC-157 in dogs for joint problems, gut issues, and post-surgical healing. However, it is not approved for veterinary use, and virtually all published evidence comes from rodent studies. If you are considering it, work with a veterinarian experienced in peptide therapy who can assess your dog's specific situation and monitor for side effects.

Is semaglutide safe for overweight pets? Semaglutide has not been adequately studied in dogs or cats. No veterinary GLP-1 medications are currently approved. Clinical trials are underway — including a GLP-1 implant for cats — but results are not yet available. Do not give your pet human semaglutide without veterinary guidance; dosing, formulation, and safety parameters have not been established.

What peptides are used in horse racing recovery? TB-500 is the most commonly discussed peptide in equine sports medicine for tendon and soft tissue recovery. Some equine practitioners also use BPC-157. Both are banned in competitive racing. Bioactive collagen peptides (PETAGILE) have been studied for equine osteoarthritis and are available as supplements.

Are antimicrobial peptides replacing antibiotics in livestock? Not yet, but they are being actively developed as alternatives. AMPs show advantages over traditional antibiotics — including lower resistance rates and biodegradability — but face challenges in cost, manufacturing scale, and regulatory approval. They are most likely to complement rather than fully replace conventional antibiotics in the near term.

How are peptide vaccines different from traditional vaccines for dogs? Traditional vaccines use weakened or killed whole pathogens. Peptide vaccines use specific protein fragments (epitopes) that trigger immune responses against targeted proteins — like EGFR/HER2 in cancer cells. They tend to be safer (no risk of accidental infection), more stable, cheaper to produce, and more precisely targeted [4].

Can peptides help with my dog's arthritis? Several peptides show promise for canine arthritis. BPC-157 has anti-inflammatory properties in animal models. GHK-Cu accelerates tissue repair. Bioactive collagen peptides have clinical data in both dogs and horses for osteoarthritis. But none are FDA-approved for this indication. Talk to your vet about combining proven treatments (weight management, NSAIDs, physical therapy, joint supplements) with any experimental approaches.

The Bottom Line

Veterinary peptide medicine sits at an interesting crosspoint. Some applications — diagnostic testing, peptide antibiotics, cancer vaccines — have solid evidence and established or pending regulatory approval. Others — BPC-157 for dogs, TB-500 for horses, GLP-1 drugs for pet obesity — show genuine promise but remain experimental.

The gap between human and veterinary peptide research is closing. Canine cancer vaccines are in advanced trials. GLP-1 implants for pets are being tested. Antimicrobial peptides are being developed as alternatives to antibiotics in livestock. These are real scientific programs, not marketing exercises.

For pet owners, the practical advice is straightforward: work with your veterinarian, demand quality sourcing, and treat experimental peptides as what they are — experimental. The most responsible path forward combines an open mind about emerging therapies with honest recognition of what we do not yet know.

For a broader look at peptides discussed in this article, see our guides to BPC-157, TB-500, GHK-Cu, semaglutide, CJC-1295, and defensins.

References

VET4BULLDOG. "Peptides for Pets: Hype, Hope, and What You Must Know." 2025. VET4BULLDOG
Bachem. "Peptides in Veterinary Medicine." White Paper. Bachem
Prescott, J.F. "Peptide Antibiotics." Antimicrobial Therapy in Veterinary Medicine, 5th Edition. Wiley. Wiley
AmbioPharm. "Peptide Vaccines in Canine Veterinary Medicine." 2024. AmbioPharm
Sikiric, P. et al. "Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review." Pharmaceuticals, 2025. PMC
The Natural Pet Doctor. "BPC-157: A Breakthrough for Pet Gut Health and Healing." 2024. TheNaturalPetDoctor
First Choice Equine. "What is TB-500 (Thymosin Beta-4 Fragment) for Horses?" 2024. First Choice Equine
Timms, M. et al. "Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4, in equine urine and plasma by liquid chromatography-mass spectrometry." Journal of Chromatography A, 2012. ScienceDirect
Pickart, L. et al. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018. PMC6073405
Drugs.com. "New GLP-1 Implant May Help Overweight Pets, Study Underway." 2025. Drugs.com
Pena-Gimenez, T. et al. "Physiological and Pharmacological Actions of Glucagon-Like Peptide-1 (GLP-1) in Domestic Animals." Veterinary and Animal Science, 2022. ScienceDirect
Robles Ramirez, H.D. et al. "Antimicrobial Peptides in Livestock: A Review with a One Health Approach." Frontiers in Cellular and Infection Microbiology, 2024. Frontiers
Saeed, S.I. et al. "Antimicrobial Peptides: Bringing Solution to the Rising Threats of Antimicrobial Resistance in Livestock." Frontiers in Veterinary Science, 2022. Frontiers
ScienceDirect. "Application of Antimicrobial Peptides in the Poultry Industry." Peptides, 2024. ScienceDirect
Stogdale, L. et al. "Specific Bioactive Collagen Peptides (PETAGILE) as Supplement for Horses with Osteoarthritis." Journal of Equine Veterinary Science, 2018. PubMed
Yale News. "Novel Cancer Vaccine Offers New Hope for Dogs — and Those Who Love Them." March 2024. Yale News
Cancer Research Alliance. "EGFR/HER2 Vaccine Study Status." 2025. CCR Alliance
Renner, U.M. et al. "A DNA Telomerase Vaccine for Canine Cancer Immunotherapy." Molecular Therapy — Oncolytics, 2019. PMC6534364

Table of Contents